FCFélicie Costantino

Félicie Costantino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Félicie Costantino has a total of 136 co-authors. Here are the top co-authors by number of shared publications:

  • Maxime Breban

    Infection & Inflammation, UMR 1173, Inserm, UVSQ/Université Paris Saclay, Montigny-Le-Bretonneux, France; Department of Rheumatology, Ambroise-Paré Hospital, AP-HP, Paris, France

    5 shared publications
  • Esperanza Naredo

    19Universitario Fundación Jiménez Díaz, IIS Fundación Jiménez Díaz, Rheumatology, Universidad Autónoma de Madrid, Madrid, Spain

    3 shared publications
  • Lene Terslev

    24 Center for Rheumatology and Spine Diseases, Rigshospitalet, Kobenhavn, Denmark

    3 shared publications
  • Maria Antonietta D'AGostino

    Division of Rheumatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino-Gemelli IRCSS, Rome, Italy

    3 shared publications
  • Maria-Antonietta D’aGostino

    Univ Paris Saclay, Infect & Inflammat, UMR 1173, Inserm,UVSQ, F-78180 Montigny Le Bretonneux, France

    3 shared publications
  • Andrew Filer

    Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), UK; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and NIHR Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Rheumatology Research Group, School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UK; Birmingham Tissue Analytics, Institute of Translational Medicine, University of Birmingham, Birmingham, UK

    2 shared publications

Latest Publications

  • Recherche de nouveaux facteurs génétiques de susceptibilité à la spondyloarthrite grâce à une approche associant études familiales et génomique fonctionnelle

    by Félicie Costantino

    La spondyloarthrite (SpA) est un rhumatisme inflammatoire chronique fréquent et invalidant. Plus d’une vingtaine de locus de susceptibilité à la maladie ont été identifiés à ce jour, dont HLA-B27 situé dans le complexe majeur d’histocompatibilité (CMH). L’objectif de ce travail était d’identifier de nouveaux facteurs génétiques de susceptibilité à la SpA grâce à une double approche d’études familiales et de génomique fonctionnelle. Dans la première partie, nous avons génotypé des familles multiplex de SpA. L’analyse de liaison non paramétrique a révélé la présence, en plus du CMH, d’un nouveau locus significativement lié à la SpA en 13q13. L’étude de ce locus nous a permis de restreindre la région d’intérêt à un intervalle de 1,3 Mb, dont le séquençage est en cours. Par ailleurs, l’étude d’association intra-familiale a identifié un SNP intronique de MAPK14 significativement associé à la SpA. Enfin, nous avons montré que l’un des SNPs du gène IL23R connu pour être associé à la spondylarthrite ankylosante était en fait associé à la présence d’une sacro-iliite radiologique dans la SpA. Parallèlement aux études familiales, nous avons comparé le transcriptome de cellules dendritiques de neuf patients atteints de SpA à celui de dix témoins sains. Nous avons ainsi identifié 81 gènes différentiellement exprimés. Nous avons aussi montré que l’expression génique d’ERAP1 (et à un moindre degré son expression protéique et son niveau d’activité enzymatique) étaient sous le contrôle de polymorphismes de ce gène associés à la SpA.

  • Dual JAK and IL-23 blockade: A mechanistically supported strategy in refractory psoriatic arthritis. A case report.

    by Paul Gervaise, Simon Glatigny, Maxime Breban, Félicie Costantino

  • Open Access

    Rethinking HLA-B27 Testing: What HLA-B27 Can—and Cannot—Tell Us

    by Marie Beaufrère, Bilade Cherqaoui, Félicie Costantino

    Yet, like any biomarker, it must be interpreted with a clear understanding of its limitations. Its sensitivity is incomplete (approximately 70-90% of patients with axSpA are HLA-B27 positive7), and its specificity is limited by a relatively high frequency in the general population (8-10% among individuals of European ancestry).8 This frequency varies considerably across ethnic groups,9 introducing potential biases in interpretation based on ancestry.10 Most importantly, the diagnostic value of HLA-B27 depends heavily on pretest probability, which itself is strongly influenced by the highly polymorphic clinical presentation of SpA. The test is most informative in patients with typical axSpA features, such as inflammatory back pain in young adults, but its diagnostic value is more limited in cases with peripheral arthritis or when SpA is associated with psoriasis or inflammatory bowel disease, where the association with HLA-B27 is weaker. To reach a clinically meaningful posttest probability (eg, > 90%), the physician’s prior suspicion should already be above 50%.11 As shown by Rudwaleit et al, in patients with chronic back pain, at least 2-3 SpA features are typically needed to reach a 90% diagnostic probability.12 In this context, HLA-B27 was one of the features with the highest positive likelihood ratio (LR+ ~9). However, a more recent metaanalysis reported lower LR+ values for HLA-B27 of around 3.13 It is also worth noting that HLA-B27–positive SpA cases may represent a more phenotypically homogeneous subgroup, with a more consistent pattern of axial involvement and inflammatory burden. Taken together, these data reinforce that HLA-B27, although valuable, should never be interpreted in isolation.


  • What is a severe axial spondyloarthritis?

    by Félicie Costantino, Maxime Breban, Maria-Antonietta D’aGostino


  • Open Access

    Identification of Symptom Phenotypes of Hand Osteoarthritis Using Hierarchical Clustering: Results From the DIGICOD Cohort

    by Marie Binvignat, Gabriel Pires, Nicolas Tchitchek, Félicie Costantino, Alice Courties, David Klatzmann, Atul J. Butte, Bernard Combe, Maxime Dougados, Pascal Richette, et al.

    Objective: We aimed to delineate phenotypes in hand osteoarthritis (HOA) based on cardinal symptoms (pain, functional limitation, stiffness, and aesthetic discomfort).Methods: With data from the Digital Cohort Design (DIGICOD), we performed a hierarchical agglomerative clustering analysis based on Australian/Canadian Osteoarthritis Hand Index (AUSCAN) subscores for pain, physical function, stiffness, and visual analog scale for aesthetic discomfort. Kruskal‐Wallis and post hoc analyses were used to assess differences between clusters.Results: Among 389 patients, we identified 5 clusters: cluster 1 (n = 88) and cluster 2 (n = 91) featured low and mild symptoms; cluster 3 (n = 80) featured isolated aesthetic discomfort; cluster 4 (n = 42) featured a high level of pain, stiffness, and functional limitation; and cluster 5 (n = 88) had the same features as cluster 4 but with high aesthetic discomfort. For clusters 4 and 5, AUSCAN pain score was >41 of 100, representing only one‐third of our patients. Aesthetic discomfort (clusters 3 and 5) was significantly associated with erosive HOA and a higher number of nodes. The highly symptomatic cluster 5 was associated but not significantly with metabolic syndrome, and body mass index and C‐reactive protein level did not differ among clusters. Symptom intensity was significantly associated with joint destruction as well as with physical and psychological burden. Patients’ main expectations differed among clusters, and function improvement was the most frequent expectation overall.Conclusion: The identification of distinct clinical clusters based on HOA cardinal symptoms suggests previously undescribed subtypes of this condition, warranting further study of biological characteristics of such clusters, and opening a path toward phenotype‐based personalized medicine in HOA.


  • Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis

    by Catherine Beauvais, Bruno Pereira, Thao Pham, Christelle Sordet, Pascal Claudepierre, Françoise Fayet, Daniel Wendling, Félicie Costantino, Laurence Carton, Laurent Grange, et al.

    Objective: To develop and validate a patient knowledge questionnaire regarding axial spondyloarthritis (axSpA).Methods: Knowledge considered essential for patients with axSpA was identified through Delphi rounds among rheumatologists, healthcare professionals (HCPs), and patients, then reformulated to develop the knowledge questionnaire. Cross-sectional validation was performed in 14 rheumatology departments to assess internal validity (Kuder-Richardson coefficient), external validity, acceptability, reproducibility (Lin concordance correlation coefficient), and sensitivity to change (knowledge score before vs after patient education sessions and effect size).Results: The Spondyloarthritis Knowledge Questionnaire (SPAKE) is a self-administered 42-item questionnaire with a 32-item short form, both scored 0 to 100, assessing knowledge of disease, comorbidities, pharmacological treatments, nonpharmacological treatments, self-care, and adaptive skills. In the validation study (130 patients; 67 [51.5%] male, mean age 43.5 [SD 12.9] yrs), the mean (SD) score of the long-form questionnaire was 71.6 (15.4), with higher scores (better knowledge) in nonpharmacological treatments and adaptive skills and lower scores in cardiovascular comorbidity and pharmacological treatments. Acceptability was good, with no missing data; the internal validity coefficient was 0.85. Reproducibility was good (0.81, 95% CI 0.72-0.89). SPAKE showed good sensitivity to change; scores were 69.2 (15.3) then 82.7 (14.0) after patient education sessions (Hedges effect size = 0.92, 95% CI 0.52-1.31).Conclusion: SPAKE is a knowledge questionnaire for patients with axSpA, developed with the involvement of HCPs and patients and reflecting current recommendations for the management of axSpA. SPAKE will be useful in assessing knowledge acquisition and self-management strategies in routine care and research.


  • EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology

    by Aurélie Najm, Félicie Costantino, Stefano Alivernini, Alessia Alunno, Elettra Bianchi, Jacqueline Bignall, Brendan Boyce, Juan D Cañete, Francesco Carubbi, Patrick Durez, et al.

    Background Synovial tissue research has become widely developed in several rheumatology centres, however, large discrepancies exist in the way synovial tissue is handled and, more specifically, how data pertaining to biopsy procedure, quality check and experimental results are reported in the literature. This heterogeneity hampers the progress of research in this rapidly expanding field. In that context, under the umbrella of European Alliance of Associations for Rheumatology, we aimed at proposing points to consider (PtC) for minimal reporting requirements in synovial tissue research. Methods Twenty-five members from 10 countries across Europe and USA met virtually to define the key areas needing evaluation and formulating the research questions to inform a systematic literature review (SLR). The results were presented during a second virtual meeting where PtC were formulated and agreed. Results Study design, biopsy procedures, tissue handling, tissue quality control and tissue outcomes (imaging, DNA/RNA analysis and disaggregation) were identified as important aspects for the quality of synovial tissue research. The SLR interrogated four databases, retrieved 7654 abstracts and included 26 manuscripts. Three OPs and nine PtC were formulated covering the following areas: description of biopsy procedure, overarching clinical design, patient characteristics, tissue handling and processing, quality control, histopathology, transcriptomic analyses and single-cell technologies. Conclusions These PtC provide guidance on how research involving synovial tissue should be reported to ensure a better evaluation of results by readers, reviewers and the broader scientific community. We anticipate that these PtC will enable the field to progress in a robust and transparent manner over the coming years.


  • Open Access

    Impact of synovial biopsy procedures and disease-specific aspects on synovial tissue outcome: a systematic literature review informing the EULAR points to consider for the minimal reporting requirements in synovial tissue research in rheumatology

    by Aurélie Najm, Félicie Costantino, Catherine Weill, Andrew Filer, Maria Antonieta D'AGostino

    Background The aim of this work was to summarise the literature evaluating the impact of biopsy procedures, tissue handling, tissue quality and disease-specific aspects including joint biopsied and disease stage, on synovial tissue outcome. Methods Two reviewers independently identified eligible studies according to the Patients, Intervention, Comparator and Outcome framework obtained for five research questions formulated during the first EULAR task force meeting to produce points to consider (PtC) for minimal reporting requirements in synovial tissue studies. The databases explored were Medline, Embase, CENTRAL and Cinhal. The risk of bias of each study was evaluated using an adapted version of the Joanna Briggs Institute checklist for analytical cross-sectional studies. Results Of the 7654 records yielded, 75 full texts were assessed, leading to the inclusion of 26 manuscripts in the systematic literature review (SLR). Two papers assessed the impact of biopsy procedures on the quality and quantity of tissue retrieved alongside patient tolerability; six papers focused on synovial tissue variability. Four papers studied the impact of sample handling or randomisation and 14 assessed the impact of disease stage and state, namely early or established active rheumatoid arthritis and remission on histopathological and transcriptomic results. Conclusions This SLR informs the EULAR PtC for minimal reporting requirements in synovial tissue research in rheumatology. Characteristics related to the study design, population, sample handling, randomisation and analysis can affect the final synovial tissue outcome in the studies reviewed. Thus, accurate reporting of these factors is required in order to ensure the scientific validity of manuscripts describing synovial tissue outcomes.


  • Cluster analysis in early axial spondyloarthritis predicts poor outcome in the presence of peripheral articular manifestations

    by Félicie Costantino, Philippe Aegerter, Georg Schett, Ann-Sophie De Craemer, Anna Molto, Filip Van Den Bosch, Dirk Elewaut, Maxime Breban, Maria-Antonietta D’aGostino

    Objectives: To assess whether two cluster analysis-based axial SpA (axSpA) endotypes (A for purely axial; B for both axial and peripheral) are stable over time and are associated with different long-term disease outcomes. Methods: K-means cluster analysis was performed at each visit (until 5 years) on 584 patients from the DESIR cohort, who completed all planned visits, and validated in 232 consecutive axSpA patients from the BeGiant cohort. Cluster stability overtime was assessed by kappa statistics. A generalized linear mixed-effect analysis was applied to compare outcomes between clusters. Classification and regression tree (CART) analysis was performed to determine a decision rule able to assign a given patient to a definite cluster at onset. Results: Both endotypes remained remarkably stable over time. In the DESIR cohort, patients in cluster B showed higher disease activity, worse functional outcome and higher need for anti-rheumatic drugs than patients in cluster A. CART analysis yielded three main clinical features (arthritis, enthesitis and dactylitis) that accurately determined cluster assignment. These results could be replicated in the Be-GIANT cohort. Conclusion: Cluster-based axSpA endotypes were reproducible in two different cohorts, stable over time and associated with different long-term outcome. The axSpA endotype with additional peripheral disease manifestations is associated with more severe disease and requires more intensive drug therapy Clinical trial registration: clinicaltrials.gov, https://clinicaltrials.gov, NCT01648907.